Page 8 - Recommended Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

NEW YORK and HONG KONG, June 14, 2022 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for unmet needs in cancer, today announced the initiation of patient dosing in TWT-203, its Phase 1b/2 study to evaluate CFI-402257, an oral, best-in-class inhibitor of Threonine Tyrosine Kinase (TTK, also known as MPS1) in patients with advanced solid tumors and ER+/Her2- breast cancer. Dosing of the first patient in the trial commenced June 8that START Mountain Region in Salt Lake City, Utah. "Inhibition of TTK, a key mitotic checkpoint, with CF...

/PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for unmet needs in cancer, today announced the...

NEW YORK and HONG KONG, June 13, 2022 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines fo...

NEW YORK and HONG KONG, June 13, 2022 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for unmet needs in cancer, today announced the

-- Interim results of tisotumab vedotin plus pembrolizumab from Phase 1b/2 innovaTV 205 trial, showing 41% objective response rate in first-line patients with recurrent or metastatic cervical cancer (r/mCC), to be presented in an oral session ---- Additional poster presentations to include debut of web-based tool fo...